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Summary
Loss of appetite and ensuing weight loss is a key feature of
severe illnesses. Protein-energy malnutrition (PEM) con-
tributes significantly to the adverse outcome of these con-
ditions. Pharmacological interventions to target appetite
stimulation have little efficacy but considerable side ef-
fects. Therefore nutritional therapy appears to be the logic-
al step to combat inadequate nutrition. However, clinical
trial data demonstrating benefits are sparse and there is no
current established standard algorithm for use of nutritional
support in malnourished, acutely ill medical inpatients. Re-
cent high-quality evidence from critical care demonstrating
harmful effects when parenteral nutritional support is used
indiscriminately has led to speculation that loss of appetite
in the acute phase of illness is indeed an adaptive, protect-
ive response that improves cell recycling (autophagy) and
detoxification. Outside critical care, there is an important
gap in high quality clinical trial data shedding further light
on these important issues. The selection, timing, and doses
of nutrition should be evaluated as carefully as with any
other therapeutic intervention, with the aim of maximising
efficacy and minimising adverse effects and costs. In light
of the current controversy, a reappraisal of how nutrition-
al support should be used in acutely ill medical inpatients
outside critical care is urgently required. The aim of this re-
view is to discuss current pathophysiological concepts of
PEM and to review the current evidence for the efficacy of
nutritional support regarding patient outcomes when used
in an acutely ill medical patient population outside critical
care.
Key words: nutrition; acute illness; malnutrition;
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Introduction
Although nutritional support using either oral nutritional
supplements (ONS) or enteral feeding is one of the most
common interventions in medicine, there is no current
standard algorithm for the use in unselected, polymorbid,
acutely ill medical inpatients at risk of protein-energy mal-
nutrition (PEM). In the light of recent high-quality evid-
ence from critical care demonstrating contrasting results,
either late beneficial effects [1], lack of benefit [2] or harm-
ful effects [3, 4] when clinical nutrition is used indiscrim-
inately and/or too aggressively, a reappraisal of how nutri-
tional therapy should be used in medical inpatients is now
required.
Several considerations support the current approach of sys-
tematically screening inpatients for PEM risk and of start-
ing nutritional therapy in at-risk patients. Epidemiological
studies from various countries and healthcare settings have
shown strong associations between PEM and patient out-
comes. For example, an observational cohort study of nu-
trition practices in 167 intensive care units (ICUs) across
37 countries including 2,772 mechanically ventilated pa-
tients found that an increase of 1,000 calories per day was
associated with a significant reduction in mortality (odds
ratio for 60-day mortality 0.76; 95% confidence interval
Figure 1
Association of PEM measured with the NRS 2002 and 30 days
mortality in a 6-month observational cohort study performed in the
Medical University Clinic at the Kantonsspital Aarau, Switzerland
[7]. In red, 30-day mortality is shown. In black, the number of
patients in different NRS risk classes are displayed.
NRS = nutritional risk screening; PEM = protein-energy malnutrition
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0.61–0.95, p = 0.014) [5]. The authors found also simil-
ar results for protein intake, with significant associations
with adverse patient outcomes. Interestingly, the effect of
nutritional therapy on patient outcomes differed according
to body mass index (BMI): effects were largest in patients
with BMI <25 or >35 kg/m2 with only little evidence of a
treatment effect in patients in the midrange (BMI 25–35).
Similar results have also been reported for noncritical-care
settings with significant associations of PEM (defined by
the nutritional risk score [NRS]) with higher risk for com-
plications, mortality and longer hospital length-of-stay [6].
An observational study from the Medical University Clinic
of the Kantonsspital Aarau, Switzerland, found increased
risk for PEM in about 30% of patients and a stepwise in-
crease in all-cause 30-day mortality (fig. 1) [7]. In ad-
dition, several observational studies found that there was
a vicious cycle, with PEM resulting in increased risk for
infection that in turn reduced food intake and worsened
PEM (reviewed in [8]). Multinational studies found strong
associations of decreased food intake and increased all-
cause mortality in hospitalised patients [9]. It has been
demonstrated that inadequate dietary intake leads to dys-
function of the immune system and to mucosal damage in
the gut, with risk for invasion of pathogens (translocation).
In acutely ill patients nutritional status may be further ag-
gravated by diarrhoea, vomiting, malabsorption, loss of ap-
petite, diversion of nutrients for the immune response and
urinary nitrogen loss, all of which increase nutrient losses
and further damage the body`s defence mechanisms [8]. In
addition, PEM is associated with adverse metabolic conse-
quences, such as catabolism and muscle wasting (reviewed
in [10]; fig. 2).
Despite these associations, causal inferences remain largely
unproven and whether provision of nutritional therapy in
the acute phase of illness has the potential to reverse these
adverse effects associated with PEM in the noncritical-care
inpatient setting remains unclear.
The aim of this review article is to discuss current patho-
physiological concepts of the effects of PEM and nutrition-
al therapy using ONS or tube feeding on patient outcomes
when used in an acutely ill medical inpatient population
outside critical care.
Nutritional risk screening
Nutrition screening aims at identifying patients with nu-
tritional deficits who benefit from further detailed nutri-
tional status assessment and nutritional therapy interven-
tions [11]. The European Society for Clinical Nutrition and
Metabolism (ESPEN) guidelines state that the purpose of
nutrition screening is to predict the probability of a better
or worse outcome due to nutrition factors and whether nu-
tritional treatment is likely to influence this. Optimally, pa-
tients admitted to acute-care hospitals should be screened
for risk of PEM within 24 hours. There are several screen-
ing tools validated for this purpose in the acute-care setting
[12]. Many institutions trigger automatic nutritional sup-
port when certain screening criteria are met for in-depth as-
sessment of patients.
Various nutrition screening tools are used in hospitals, but
many of them have not been well validated for the acute-
care setting. Thus, it is unclear if they appropriately identi-
fy patients who need further nutrition assessment and po-
tentially nutritional therapy. The most widely used tools
are the Nutritional Risk Screening (NRS) 2002, the Mal-
nutrition Universal Screening Tool (MUST), the subjective
global assessment of nutritional status (SGA) and the Mini
Nutritional Assessment® (MNA) (reviewed in [12]). These
screening instruments differ in the variables included and
patient populations to be targeted, and either assess patients
for the presence of malnutrition (SGA, MNA) or for being
at risk for malnutrition (MUST, NRS). Among them, the
NRS 2002 is recommended by ESPEN as the preferred
screening tool for hospitalised patients. The NRS 2002 was
developed by Kondrup and colleagues based on a retro-
spective analysis of controlled trials [13]. Their premise
was that the indications for nutritional support should de-
pend on two factors: (i.) the severity of impaired nutritional
status and (ii.) the increase in nutrition requirements res-
ulting from disease (stress metabolism). For this reason,
the NRS 2002 includes both a measure of current potential
undernutrition and a measure of disease severity. In addi-
tion, older age is considered a risk factor, with an additional
point added for age ≥70 years. A score of ≥3 is the gener-
ally accepted cut-off, which indicates the need to start nu-
tritional therapy.
The NRS 2002 tool performed well in a validation study in-
cluding 128 controlled nutrition support trials and was cap-
able in identifying patients who would or would not benefit
from nutritional intervention [13]. In fact, the likelihood ra-
tio for a positive effect at cut-offs of 3.0 and 4.0 points were
1.7 and 5.0. As an important limitation to the medical inpa-
tient setting, most of the included trials were surgical trials
and none of them included the typical acutely ill medical
inpatient population outside the ICU. In addition, a subse-
quent prospective, controlled trial with 212 hospitalized pa-
tients did not show significant effects of nutritional therapy
in regard to mortality, hospital length-of-stay or quality of
life [14]. Thus, there is remaining uncertainty about the po-
tential of the NRS 2002 to identify patients who will bene-
fit from nutritional therapy in the medical inpatient setting.
Figure 2
The complex interaction of acute illness and cachexia is mediated
by various mechanisms (adapted from [10]).
CRP = C-reactive protein; GLP-1 = glucagon-like peptide-1; IL =
interleukin; TNF-α = tumour necrosis factor-α
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Pathophysiology of PEM due to acute
and chronic illness
Acute and chronic illness is associated with loss of appetite
and poor nutritional intake, frequently associated with a
proinflammatory state, and loss of lean and adipose tissue.
Cachexia is the result of various metabolic pathways and
mechanisms [10, 15]. Weight loss associated with acute
and chronic illness may result directly from caloric
deprivation due to loss of appetite, as well as from de-
hydration and sarcopenia. Also, hormonal imbalance with
an increase in glucocorticoid hormones and a decrease in
testosterone and other sexual steroids may further enhance
catabolism and aggravate PEM (fig. 2). Nonetheless, al-
though numerous acute medical diseases are associated
with cachexia, the underlying pathophysiological mechan-
isms remain ill defined.
Recent investigations point to the central role of cytokines
in the pathogenesis of cachexia. This relationship between
acute disease and cachexia may well be bidirectional, with
illness affecting nutritional status, and dietary factors in-
fluencing the inflammatory response and the course of ill-
ness. Cytokines are released in the body as part of the
systemic inflammatory response associated with acute ill-
nesses and have been implicated in the aetiology of anorex-
ia, weight loss, cognitive dysfunction, anaemia, and frailty
mediated by different mechanisms. Cytokines, such as in-
terleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α),
influence brain circuitries that control food intake, delayed
gastric emptying and skeletal muscle catabolism [16, 17].
Cytokines not only activate nuclear transcription factor κB
(NF-κB) resulting in decreased muscle protein synthesis,
but also reduce MyoD protein, a transcription factor that
modulates signalling pathways involved in muscle devel-
opment (fig. 2) [18, 19]. TNF-α and interferon-γ act syn-
ergistically to inhibit the activation of messenger ribonuc-
leic acid (RNA) for myosin heavy chain synthesis and
thereby stimulate the proteolysis of myosin heavy chains
[19]. Cytokines also activate the ubiquitin-mediated pro-
teolytic system, which plays a key role in disease-related
hypercatabolism [20]. Ubiquinated proteins and subse-
quent muscle proteolysis provide amino acids that are con-
sumed in hepatic synthesis of acute-phase proteins such as
C-reactive protein. Additionally, cytokines are able to mod-
ulate the response of the hypothalamic-pituitary-adrenal
axis at each level and stimulate the release of various stress
hormones including cortisol and catecholamines, which in
turn lead to an increase in resting metabolic rate [21, 22].
Other hormones that may be important for the development
of cachexia are incretin hormones such as glucagon-like
peptide-1 (GLP-1) released directly from gut tissues. Re-
cent evidence found a cross-talk of inflammatory cytokines
(mainly IL-6 and IL-1β) and GLP-1 and its analogues that
resulted in reduced food intake and thus eventually weight
loss [23]. Although this effect is beneficial in obese diabet-
ic patients, it may negatively affect malnourished acutely
ill medical patients. Synergistically, these various activated
pathways during acute illness result in negative energy bal-
ance and weight loss – ultimately resulting in cachexia and
PEM.
Loss of appetite may develop during hospital stays either
as a consequence of an underlying medical condition (e.g.,
pneumonia) or medical treatments (e.g., pain medication,
chemotherapy), or may pre-exist as a primary condition
owing to depression, social isolation and advanced age.
This distinction maybe important as it impacts the effects
of nutritional interventions. As loss of appetite secondary
to acute disease may be seen as an evolutionary process,
there is an ongoing debate about possible biological ex-
planations why the human body adapts in such a manner
during acute disease. Interestingly, there are some preclin-
ical and clinical studies suggesting that starvation may in-
deed improve cell recycling by induction of autophagy, a
survival mechanism serving to recycle intracellular nutri-
ents such as toxic protein aggregates and damaged organ-
elles [24]. In a recent animal study, early parenteral nu-
trition – particularly proteins and lipids – suppressed the
ubiquitin-proteasome pathway [25]. This contributes to the
preservation of muscle mass, but also leads to autophagy
deficiency in liver and skeletal muscle. Thus the mainten-
ance of muscle mass might come at the price of accumu-
lation of toxic protein aggregates that ultimately comprom-
ises cell function. A similar observation was also made in
critically ill patients [26] and was recently shown to con-
tribute to mitochondrial dysfunction, organ failure and ad-
verse outcome in a rabbit model of critical illness [27].
Based on these observations, it is tempting to speculate that
starvation during the early phase of acute illness may in-
deed have some beneficial effects and improves the cell re-
cycling system. At which time point these beneficial effects
may become harmful as a result of progressive catabolism
and PEM remains unclear today.
Clinical trials
Different randomised controlled trials (RCTs) have invest-
igated the effects of nutritional support using ONS and/
or enteral feeding on patient outcomes in the medical in-
patient setting. These trials have looked at different types
of outcomes including clinical outcome (physician focus),
quality of life and recovery duration (patient focus), and
costs (healthcare system focus). Table 1 shows a summary
of the most recent RCTs focusing on different patient pop-
ulations. The two trials conducted in Switzerland [28, 29]
included an individual nutritional therapy intervention aim-
ing to improve energy and protein intake. According to
individual patient's preferences and needs, hospital stand-
ard food combined with dietician counselling and interven-
tions: fortification measures and beverages, snacks, protein
powder, maltodextrin and/or ONS. The control group in
both trials received either energy-dense ONS without di-
etician counselling [29] or standard nutritional care includ-
ing ONS or nutritional therapy on request if considered
necessary by the independent treating physician [28]. As
a result, protein intake [28] or energy and protein intake
[29] was increased in the intervention group compared
with the control group during study period. This provides
strong evidence that individualised nutritional counselling
and support improves energy intake in malnourished med-
ical inpatients. Owing to the small sample size, it remains
unclear from these trials whether or not an increase in en-
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ergy and protein intake results in improved patient out-
come. Importantly, quality of life measured with either the
Function Assessment Anorexia-Cancer Therapy (FAACT)
tool and visual analogue scale (VAS) [29] or the SF36
questionnaire [28] was improved in the intervention group
in both trials. As a limitation, improvement in quality of
life may also be attributable to the intervention per se, i.e.,
the higher attention provided to patients during the study
period.
The RCT conducted by Starke et al. [28] with a sample size
of 134 patients (67 intervention group, 67 control group)
found a lower rate of in-hospital complications, use of an-
tibiotics and readmissions associated with the intervention.
However, the trial failed to demonstrate a benefit in regard
to mortality or hospital length-of-stay (LOS). Again, the
sample size was small and the trial thus underpowered to
find such effects.
Other trials used more standardised nutritional protocols
instead of individualised nutritional treatment strategies.
In 2006, Gariballa et al. [30] published the results from
a large, randomised, double-blind, placebo-controlled trial
comparing daily energy- and protein-rich ONS with a
placebo drink containing a minimal amount of calories and
without any protein in a geriatric acutely ill medical patient
population. Overall, adherence to the intervention (ONS as
well as placebo) was low, with only around 50% of the
study population consuming more than half of the amount
provided to them. The authors found significant changes in
red-cell folate and vitamin B12 after 6 weeks, as well as
lower readmission rates after 6 months, in the intervention
group, whereas all other patient-relevant outcomes includ-
ing LOS, disability measured with the Barthel Index, mor-
tality and infections remained similar in both groups.
Outside the acute care medical inpatient setting, where
ONS treatment resulted in only subtle improvements in pa-
Table 1: Overview of most recent randomised controlled trials evaluating nutritional therapy in medical inpatients. Trials using parenteral nutrition are excluded.
Author, year Population
and No.
Treatment of the
nutritional intervention
group
Treatment of the
control group
Endpoints Limitations Main results
Rüfenacht U,
2010 [29]
Adult patients admitted
to a general medical
ward, NRS ≥3
n = 53
ONS 400 ml daily,
600 kcal, 24 g protein
and individual nutritional
counselling
Only ONS 400 ml daily,
600 kcal, 24 g protein
Energy and protein
intake, LOS, QoL
(functional assessment
anorexia cancer therapy
[FAACT] and VAS)
QoL difference only at
one time point,
confounding by intensive
nutritional care possible
Significant
increase in
energy and
protein-intake as
well as QoL
Starke J, 2011
[51]
Adult patients admitted
to a general medical
ward, NRS ≥3
n = 132
Individual nutritional
care, including detailed
nutritional assessment,
individual food supply,
fortification of meals, in-
between snacks and
ONS
Standard nutritional care Daily energy and protein
intake, weight,
complications, antibiotic
therapy of infectious
complications, LOS,
QoL, hospital
readmission, mortality,
compliance with
supplement
consumption, Levels of
25-OH-vitamin D3,
ascorbic acid and
glutathione
No functional outcome
assessed
Intervention
beneficial for
nutritional status
Qol, fewer
complications and
rehospitalisations
Potter JM, 2001
[49]
Patients admitted to a
“general medical ward
for the elderly” (>60 y)
any kind of nutritional
status
n = 381
Protein energy sip feed
supplement containing
1.5 kcal/ml energy
intended to provide 22.5
g protein and 540 kcal/d.
Three times daily 120 ml
Normal ward diet and
snacks, dietetic
intervention available to
all patients in the study
Weight, arm muscle
circumference, triceps
skinfold thickness, BMI,
20-point Barthel ADL,
survival, discharge
destination, LOS, energy
intake
Lower mortality,
better functional
outcome in
severely
malnourished
patients after
intervention
Gariballa S,
2006 [52]
Patients over age 65 y,
medical or surgical (not
GI surgery) diagnosis,
any kind of nutritional
status
n = 445
400 ml ONS in addition
to standard hospital diet
Placebo with minimal
calorie content (60 kcal)
Barthel score,
nonelective
readmissions, LOS,
discharge destination,
morbidity and mortality
Nonsignificant results in
primary endpoints
No significant
effect of
intervention
Hickson M,
2004 [53]
Patients ≥65 years of
age, admitted to a
“medicine for the elderly
ward”, any kind of
nutritional status
n = 592
Encouragement of
patients, offering of
snacks and drinks
Standard hospital diet
alone
LOS, Barthel, weight,
MAC, TSF, albumin,
abbreviated mental test,
intake, infection rate
measured by antibiotic
use, fluid use, in hospital
mortality.
Intervention conducted
by nondieticians
(healthcare assistants)
Employing extra
healthcare
assistants in
preventing weight
loss is not
effective
Johansen N,
2004 (12)
Adult patients admitted
for medical disease or
surgical diagnosis or
interventions,
nutritionally at risk
n = 212
Nutritional team for
motivation, estimation of
requirements, advice
and assurance of
adequate nutrition
Usual care LOS-NDI (nutritional
discharge index) SF-36
QoL, intake of energy
and protein, use of
antibiotics
Inclusion of surgical and
medical patients
No differences in
rate of
complications and
LOS
ADL = activities of daily living; BMI = body mass index; d = day(s); GI = gastrointestinal; h = hours(s); LOS = length of stay; m = month(s); NRS = nutritional risk screening;
ONS = oral nutritional supplement; QoL = quality of life; VAS = visual analogue scale
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tient outcomes, ONS was associated with important im-
provements in long-term institutionalised malnourished
geriatric patients and in perioperative patients in some tri-
als [31, 32]. But also in this setting, not all trials found
such effects and the benefit of ONS remains somewhat un-
clear [33]. A major shortcoming in the above mentioned
trials was low protocol adherence and thus nutritional tar-
gets were not met. Whether this was the main reason for
the lack of significant results remains debated. Outside crit-
ical care, trials using enteral and/or parenteral nutrition to
reach nutritional targets and that could shed a light on this
important issue are lacking.
Current evidence from RCT data is inconsistent regarding
the effectiveness of different nutritional strategies in the
acutely ill inpatient setting. However, all the above-men-
tioned trials were relatively small, highly heterogeneous in
design, patient populations and type of intervention, and
lacked statistical power to demonstrate safety and, alto-
gether, produced inconclusive results. Blinding of therapy
was not performed since this is not feasible when nutri-
tional interventions are used. This could also have res-
ulted in an investigator bias. Unsurprisingly, two previ-
ous aggregate data meta-analyses confirm the important
lack of high-quality evidence to endorse or refute nutri-
tional support [33, 34]. Both meta-analyses, however, were
based on aggregate data only and did not specifically ex-
amine the effect of early nutritional therapy in medical in-
patients. Rather, one meta-analysis focused on such therapy
in critical-care/perioperative patients [34], and the other
only considered general protein and energy supplementa-
tion in the elderly [33]. Moreover, having been published
in 2007 and 2009, respectively, neither meta-analysis cap-
tures the most recent work.
Guideline recommendations of
European and American professional
societies
Considerable efforts have been made to standardise nutri-
tional treatment on an inpatient and outpatient basis. Na-
tional and international consensus committees developed
and published guidelines focusing each on distinct medical
conditions and different indications [35–46]. The most im-
portant guidelines are from the American Society for Par-
enteral and Enteral Nutrition (ASPEN) and ESPEN. Most
of the recommendations, however, are based on small trials
in selected patient populations, and recommendations for
general medical inpatients do not exist currently. Due to
the lack of high quality clinical data, most guidelines give
only weak recommendations and no unequivocal instruc-
tions on patient selection, the time-points when to start and
stop, route, amount and duration of nutritional support. As
a result and despite widespread acceptance, implementa-
tion of nutritional guidelines is still insufficient [47]. Also,
the substantial differences between national and interna-
tional guidelines may further slow down the widespread
implementation of guidelines. In the case of renal failure,
for instance, the ASPEN guidelines [37] recommend adapt-
ing energy and protein targets based on the requirements
measured by indirect calorimetry and nitrogen balance. In
contrast, ESPEN guidelines [38] specify general targets
for micro- and macronutrients for each stage of acute and
chronic renal failure. However, neither guideline gives spe-
cific recommendations about the time-point, route of deliv-
ery and amount of nutritional therapy (energy) in this situ-
ation. Importantly, malnutrition may exists before hospital
admission, and develop and/or aggravate during the hospit-
al stay, which should also influence the medical strategy for
treatment of the patients in question [48, 49]. In addition,
to our knowledge few published data included analysis of
the barriers to the practical implementation of nutritional
guidelines [50]. However, it can be assumed these would
include unawareness and insufficient knowledge, ethical
considerations and patient resistance among others.
Conclusions and outlook
Although the use of nutritional therapy involving dietary
counselling, ONS or enteral nutrition is one of the most
common interventions in medical inpatients, there is no
current scientific clear evidence of its efficacy, and stand-
ard algorithms for its use in acutely ill medical inpatients at
risk of PEM are generally lacking. In light of recent high-
quality evidence from parenteral nutrition in critical care, a
reappraisal of how nutritional support should be implemen-
ted in acutely ill medical patients is now required. The se-
lection, timing, dose and feasibility of nutritional treatment
should be evaluated as carefully as with any other thera-
peutic interventions, with the aim of maximising efficacy
and minimising side effects and costs.
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Figures (large format)
Figure 1
Association of PEM measured with the NRS 2002 and 30 days mortality in a 6-month observational cohort study performed in the Medical
University Clinic at the Kantonsspital Aarau, Switzerland [7]. In red, 30-day mortality is shown. In black, the number of patients in different NRS
risk classes are displayed.
NRS = nutritional risk screening; PEM = protein-energy malnutrition
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Figure 2
The complex interaction of acute illness and cachexia is mediated by various mechanisms (adapted from [10]).
CRP = C-reactive protein; GLP-1 = glucagon-like peptide-1; IL = interleukin; TNF-α = tumour necrosis factor-α
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